These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9647284)

  • 1. Magnetic resonance imaging techniques to monitor short term evolution of multiple sclerosis and to use in preliminary trials.
    Miller DH; Frank JA
    J Neurol Neurosurg Psychiatry; 1998 May; 64 Suppl 1():S44-6. PubMed ID: 9647284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
    Miller DH; Albert PS; Barkhof F; Francis G; Frank JA; Hodgkinson S; Lublin FD; Paty DW; Reingold SC; Simon J
    Ann Neurol; 1996 Jan; 39(1):6-16. PubMed ID: 8572668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.
    Harris JO; Frank JA; Patronas N; McFarlin DE; McFarland HF
    Ann Neurol; 1991 May; 29(5):548-55. PubMed ID: 1859184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.
    Kappos L; Moeri D; Radue EW; Schoetzau A; Schweikert K; Barkhof F; Miller D; Guttmann CR; Weiner HL; Gasperini C; Filippi M
    Lancet; 1999 Mar; 353(9157):964-9. PubMed ID: 10459905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis--preliminary results.
    Losseff NA; Miller DH; Kidd D; Thompson AJ
    Mult Scler; 2001 Feb; 7(1):23-5. PubMed ID: 11321189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
    Barkhof F; Scheltens P; Frequin ST; Nauta JJ; Tas MW; Valk J; Hommes OR
    AJR Am J Roentgenol; 1992 Nov; 159(5):1041-7. PubMed ID: 1414773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis pathology and to monitor definitive clinical trials.
    Paty DW; McFarland H
    J Neurol Neurosurg Psychiatry; 1998 May; 64 Suppl 1():S47-51. PubMed ID: 9647285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials.
    Frank JA; Stone LA; Smith ME; Albert PS; Maloni H; McFarland HF
    Ann Neurol; 1994; 36 Suppl():S86-90. PubMed ID: 8017894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis.
    Filippi M; Yousry T; Rocca MA; Fesl G; Voltz R; Comi G
    Acta Neurol Scand; 1997 Jun; 95(6):331-4. PubMed ID: 9228265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis.
    Giugni E; Pozzilli C; Bastianello S; Gasperini C; Paolillo A; Koudriavtseva T; Frontoni M; Farina D; Bozzao L
    Mult Scler; 1997 Aug; 3(4):221-5. PubMed ID: 9372503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis.
    Lai M; Hodgson T; Gawne-Cain M; Webb S; MacManus D; McDonald WI; Thompson AJ; Miller DH
    J Neurol Neurosurg Psychiatry; 1996 Mar; 60(3):339-41. PubMed ID: 8609517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging.
    Lee MA; Smith S; Palace J; Matthews PM
    Brain; 1998 Nov; 121 ( Pt 11)():2095-102. PubMed ID: 9827769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Magnetic resonance imaging in multiple sclerosis].
    Tourbah A; Berry I
    Pathol Biol (Paris); 2000 Mar; 48(2):151-61. PubMed ID: 10815291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.
    Stone LA; Frank JA; Albert PS; Bash C; Smith ME; Maloni H; McFarland HF
    Ann Neurol; 1995 May; 37(5):611-9. PubMed ID: 7755356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups.
    Tubridy N; Ader HJ; Barkhof F; Thompson AJ; Miller DH
    J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):50-5. PubMed ID: 9436727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.
    McFarland HF; Frank JA; Albert PS; Smith ME; Martin R; Harris JO; Patronas N; Maloni H; McFarlin DE
    Ann Neurol; 1992 Dec; 32(6):758-66. PubMed ID: 1471866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lesion in multiple sclerosis: clinical, pathological, and magnetic resonance imaging considerations.
    McFarland HF
    J Neurol Neurosurg Psychiatry; 1998 May; 64 Suppl 1():S26-30. PubMed ID: 9647281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.